Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

<p>Shows Phenotype, Viability, and Cytotoxicity of the Product.</p>

保存先:

書誌詳細
第一著者:	Ulka N. Vaishampayan (15051039) (author)
その他の著者:	Archana Thakur (15051042) (author), Wei Chen (15051045) (author), Abhinav Deol (15051048) (author), Meera Patel (15051051) (author), Kimberlee Dobson (15051054) (author), Brenda Dickow (15051057) (author), Dana Schalk (15051060) (author), Amy Schienschang (15051063) (author), Sarah Whitaker (15051066) (author), Amanda Polend (15051069) (author), Joseph A. Fontana (411960) (author), Elisabeth I. Heath (15024674) (author), Lawrence G. Lum (15051072) (author)
出版事項:	2025
主題:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料